Nanoform Finland Plc | Press Release | May 06, 2025 at 11:00:00 EEST
Helsinki, Finland – Nanoform Finland Plc (“Nanoform”), the medicine performance-enhancing company, will publish its Q1 2025 report May 20th, 2025, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time.
The company will hold an online presentation and conference call the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time. Nanoform will be represented by CEO Edward Hæggström, CFO Albert Hæggström, CCO Christian Jones and CDO Peter Hänninen. The presentation will be delivered in English.
The presentation will be broadcasted live and participants may access the event via audiocast and teleconference through the following link:
https://investorcaller.com/events/nanoform/nanoform-q1-report-2025
To participate in the event, attendees are required to register. To join the Q&A session, attendees must access the teleconference by dialling in. Upon registration, participants will receive a dial-in number, a conference ID, and a personal User ID to access the conference. Please note that questions can only be submitted through the teleconference line.
For further information, please contact:
Henri von Haartman, Director of Investor Relations
hvh@nanoform.com
+46 7686 650 11
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale. Nanoform will help improve bioavailability and drug delivery profiles, drive differentiation, patient adherence and extend the lifecycle potential of products. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Carnegie Investment Bank AB (publ), +46 8-588 68 570. For more information, please visit www.nanoform.com.